CA-125 monitored therapy with GnRH analogue of pelvic endometriosis

P Negri, Pedro Negri, Negri P, Melissa Ricciardelli, Ricciardelli MA, M A Ricciardelli, Tomasi A, A. Tomasi, Elisa Grechi, E Grechi, Grechi E, Fortini RM, R M Fortini
Acta Europaea fertilitatis · 1994 · vol. 23(4) , pp. 171–4 · PMID:1343472 · W2413799565
Other OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-09-29 ⓘ

This study monitored CA-125 serum levels in thirteen patients with pelvic endometriosis treated with the GnRH analogue Buserelin to evaluate its utility for individualized follow-up based on pre- and post-treatment graphs.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Thirteen patients affected by endometriosis have been treated with GnRH analogue Buserelin. CA-125 serum levels have been monitored before, during and after treatment. Analysis of data suggests the hypothesis of an individualized follow up by means of repeated assays of CA-125 and their reference to pre and post treatment graphs.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antigens, Tumor-Associated, Carbohydrate Buserelin Endometriosis Pelvic Neoplasms Adult Adult Analysis of Variance Analysis of Variance Antigens, Tumor-Associated, Carbohydrate Antigens, Tumor-Associated, Carbohydrate Buserelin Buserelin Buserelin Endometriosis Endometriosis Endometriosis Endometriosis Estradiol Estradiol Estradiol

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-26T06:15:05.866214+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:01:29.034871+00:00
License: CC0 · commercial use OK